Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Single-dose open-label mass balance and pharmacokinetic study of 14C-BCT197 in healthy male volunteers
NL-OMON36837Active, not recruiting
- Sponsor
- Novartis
- Start
- Oct 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label trial of acumapimod in chronic obstructive pulmonary disease (COPD), sponsored by Novartis. Primary endpoints: Quantification of BCT197 and metabolites, Pharmacokinetics of total radioactivity and 7 more. Started Oct 2012; status: active, not recruiting.
02
Drugs
acumapimod
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NL-OMON36837.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON36837.